share_log

復星醫藥：關連交易 - 訂立股權轉讓協議

FOSUN PHARMA: CONNECTED TRANSACTION - ENTERING INTO THE EQUITY TRANSFER AGREEMENT

HKEX ·  May 31 21:32

Summary by Futu AI

上海復星醫藥（集團）股份有限公司（簡稱復星醫藥）於2024年5月31日宣布，其附屬公司佛山復星禪醫已與星雙健投資簽訂股權轉讓協議。根據該協議，佛山復星禪醫將以人民幣131,146元的現金對價收購星雙健投資持有的目標公司49%的股權，使佛山復星禪醫的持股比例增至100%。目標公司是一家專注於醫養結合的高端養護院，目前處於開業籌建階段，預計2024年第四季度投入運營。此次交易構成關連交易，但由於最高適用百分比率低於5%，故按香港上市規則豁免獨立股東批准。復星醫藥表示，此次收購有助於深化集團在醫養結合領域的實踐和經驗積累，並強化佛山復星禪醫在提供中高端醫養服務方面的專業醫療資源。
上海復星醫藥（集團）股份有限公司（簡稱復星醫藥）於2024年5月31日宣布，其附屬公司佛山復星禪醫已與星雙健投資簽訂股權轉讓協議。根據該協議，佛山復星禪醫將以人民幣131,146元的現金對價收購星雙健投資持有的目標公司49%的股權，使佛山復星禪醫的持股比例增至100%。目標公司是一家專注於醫養結合的高端養護院，目前處於開業籌建階段，預計2024年第四季度投入運營。此次交易構成關連交易，但由於最高適用百分比率低於5%，故按香港上市規則豁免獨立股東批准。復星醫藥表示，此次收購有助於深化集團在醫養結合領域的實踐和經驗積累，並強化佛山復星禪醫在提供中高端醫養服務方面的專業醫療資源。
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (ABBREVIATED AS FUSTAR PHARMACEUTICALS) ANNOUNCED ON 31 MAY 2024 THAT ITS SUBSIDIARY FOSHAN FUXING ZEN MEDICAL HAS SIGNED AN EQUITY TRANSFER AGREEMENT WITH STARSHUNJIAN INVESTMENT. UNDER THE AGREEMENT, FOSHAN FUSTAR ZEN WILL ACQUIRE 49% OF THE SHARES OF THE TARGET COMPANY HELD BY STAR SHUNJIAN INVESTMENT AT RMB131,146 FOR RMB131,146, INCREASING FOSHAN'S HOLDING RATIO TO 100%. The target company is a high-end nursing home focused on the combination of medical care, which is currently in the opening phase and is expected to be operational in the fourth quarter of 2024. This transaction constitutes a connected transaction but is exempt from independent shareholder approval under the Hong Kong Listing Rules as the maximum applicable percentage is less than 5%. FUSTAR PHARMACEUTICALS SAID THAT THE ACQUISITION WILL HELP DEEPEN THE GROUP'S PRACTICE AND EXPERIENCE IN THE FIELD OF MEDICAL BLENDING AND STRENGTHEN FOSHAN FUSTAR ZEN'S PROFESSIONAL MEDICAL RESOURCES IN PROVIDING MID-TO-HIGH END MEDICAL SERVICES.
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (ABBREVIATED AS FUSTAR PHARMACEUTICALS) ANNOUNCED ON 31 MAY 2024 THAT ITS SUBSIDIARY FOSHAN FUXING ZEN MEDICAL HAS SIGNED AN EQUITY TRANSFER AGREEMENT WITH STARSHUNJIAN INVESTMENT. UNDER THE AGREEMENT, FOSHAN FUSTAR ZEN WILL ACQUIRE 49% OF THE SHARES OF THE TARGET COMPANY HELD BY STAR SHUNJIAN INVESTMENT AT RMB131,146 FOR RMB131,146, INCREASING FOSHAN'S HOLDING RATIO TO 100%. The target company is a high-end nursing home focused on the combination of medical care, which is currently in the opening phase and is expected to be operational in the fourth quarter of 2024. This transaction constitutes a connected transaction but is exempt from independent shareholder approval under the Hong Kong Listing Rules as the maximum applicable percentage is less than 5%. FUSTAR PHARMACEUTICALS SAID THAT THE ACQUISITION WILL HELP DEEPEN THE GROUP'S PRACTICE AND EXPERIENCE IN THE FIELD OF MEDICAL BLENDING AND STRENGTHEN FOSHAN FUSTAR ZEN'S PROFESSIONAL MEDICAL RESOURCES IN PROVIDING MID-TO-HIGH END MEDICAL SERVICES.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Related Stocks Related Stocks
    Symbol Mini Chart Latest Price
    SINOLIFE UTD
    03332
    -- 0.660
    TIANDA PHARMA
    00455
    -- 0.178
    NT PHARMA
    01011
    -- 0.300
    KONTA CHINA
    01312
    -- 0.032
    ZHONGZHIPHARM
    03737
    -- 0.960

    Unlock the Full List